187085-97-8

Basic information

• Product Name: (RS)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE
• Synonyms: (RS)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE;(RS)-1-[3,5-Bis(trifluoromethyl)phenyl]ethylamine min;1-[3,5-Bis(trifluoromethyl)phenyl]ethylamine;3,5-Bis(trifluoromethyl)-alpha-methylbenzylamine 97% min;1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHANAMINE;3,5-Bis(trifluoromethyl)-alpha-methylbenzylamine 97+%;Benzenemethanamine, a-methyl-3,5-bis(trifluoromethyl)-
• CAS NO: 187085-97-8
• Molecular Formula: C₁₀H₉F₆N
• Molecular Weight: 257.18
• Mol File: 187085-97-8.mol

Chemical Properties

• Boiling Point: 168.9°Cat760mmHg
• Flash Point: 66.3°C
• Appearance: /
• Density: 1.327g/cm³
• CAS DataBase Reference: (RS)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (RS)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE(187085-97-8)
• EPA Substance Registry System: (RS)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE(187085-97-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 187085-97-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(RS)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE is utilized as a key intermediate in organic synthesis for the preparation of various complex organic molecules. Its electron-withdrawing nature and reactivity make it a valuable building block for the development of novel chemical entities.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (RS)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE serves as a potential precursor for the synthesis of diverse pharmaceutical compounds. Its unique structural features and reactivity contribute to the discovery and development of new drugs with improved therapeutic properties.
Used in Medicinal Chemistry:
(RS)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE is employed in medicinal chemistry as a structural motif for the design and optimization of drug candidates. Its electron-withdrawing properties can modulate the pharmacokinetic and pharmacodynamic profiles of drug molecules, leading to enhanced efficacy and selectivity.
Used in Drug Development:
In the field of drug development, (RS)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE plays a crucial role in the synthesis of lead compounds and the optimization of drug candidates. Its unique properties and reactivity facilitate the exploration of new chemical space and the identification of novel therapeutic agents with improved safety and efficacy profiles.
Overall, (RS)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE is a versatile and valuable compound with broad applications in the fields of chemistry and drug development. Its unique structural features and reactivity make it an indispensable tool for the synthesis of complex organic molecules and the development of innovative pharmaceutical compounds.

Upstream product

• 374822-27-2 (RS)-α-methyl-3,5-bis(trifluoromethyl)benzenemethanamine hydrochloride 
• 690653-26-0 N-(bis[trifluoromethyl]phenylethyl)phthalimide 

Downstream Products

• 374819-29-1 (RS)-4-oxo-1-phenyl-N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide 
• 690653-27-1 N-butoxycarbonyl-bis-(trifluoromethyl)phenylethylamine 
• 1195172-63-4 1-(1-(3,5-bis(trifluoromethyl)-phenyl)ethyl)-3-(4-(2-methylpyridin-4-yl)phenyl)urea 
• 127733-40-8 (S)-α-(3,5-bis(trifluoromethyl)phenyl)ethylamine 
• 127733-47-5 (R)-α-(3,5-bis(trifluoromethyl)phenyl)ethylamine 

Relevant articles and documents

GAMMA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, W, X, and n are defined herein, which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

Cyclohexyl derivatives and their use as therapeutic agents

The present invention relates compounds of the formula (I): wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of: (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R?17, R18, R19, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.